The journal club gives a forum to participate and listen to discussion on different topics. Who is this event intended for? Anyone with an interest in Survival Analysis including discussions on sample size calculations, non-parametric survival comparisons and methods allowing for delayed treatment effects. What is the benefit of attending? People should attend to learn more about the different techniques and applications of survival analysis methods for delayed treatment effects and non-proportional hazards.
Please join us to hear Dominic Magirr (Novartis) and Chang Yu (Vanderbilt University) present their recent work. The webinar will be chaired by Jennifer Rogers (PHASTAR).
For each of these published papers there will be a 20 minute presentation by author followed by a 10 minute discussion.
Papers will be made available to view prior to the meeting and presentation slides will be available a week before the JC. Journal subscribers can access papers at any time. Audio recordings will be available shortly after the JC to download from the PSI website.
The meetings are open to both PSI and non-PSI members.
PSI VisSIG Wonderful Wednesdays
Our monthly webinar explores examples of innovative data visualisations relevant to our day to day work. Each month a new dataset is provided from a clinical trial or other relevant example, and participants are invited to submit a graphic that communicates interesting and relevant characteristics of the data.
The field of data visualization is the intersection of data journalism, statistics, graphic design, computer science, neuroscience, and cognitive psychology. We will focus on the latter two fields of data visualization as it relates to data visualization: neuroscience and cognitive psychology.
PSI One-Day Meeting: Missing Data in Clinical Trials - Past, Present and Future
At this meeting we will present the evolution of missing data approaches, looking at how they have been handled in the past, the current established missing data approaches and the impact of the new ICH E9 R1 addendum on the handling of missing data, focussing in particular on the treatment policy estimand.
R is quickly gaining popularity within the pharmaceutical industry due to it being a very powerful object-orientated language, and is able to produce analyses and high quality graphics. This will be a hands-on interactive course and will utilise the RStudio Cloud development environment.
As a statistician in the Biostatistics and Programming Department, you will be responsible for the methodological and statistical aspects of projects in early clinical development in order to optimize the early development plan and ensure its coherence.
As a Director of Statistics, you will be accountable for guiding statisticians in their work, performing senior review of documentation and output deliveries, providing oversight and advising on best practices approach to statistics for clinical trials.